Promising Phase 3 Trial Results for Ulcerative Colitis Therapy Xeljanz Announced by Pfizer

Promising Phase 3 Trial Results for Ulcerative Colitis Therapy Xeljanz Announced by Pfizer
Pfizer has just announced top-line results from OCTAVE Sustain, the third Phase 3 study investigating Xeljanz (tofacitinib citrate) in patients with moderate-to-severe active ulcerative colitis (UC). The OCTAVE Clinical Development Program includes three studies – OCTAVE Induction 1, OCTAVE Induction 2 and OCTAVE Sustain, in addition to a long-term extension trial, OCTAVE Open. Phase 3 OCTAVE Sustain (oral clinical trials for Xeljanz in ulcerative colitis) is a randomized, double-blind, placebo-controlled, parallel group, multi-center, 52-week trial assessing two daily doses of oral Xeljanz (5 mg and 10 mg) as a mai
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *